advertisement

Topcon

Abstract #106074 Published in IGR 23-3

Factors associated with low prevalence of Fuchs' uveitis syndrome in Japan

Yoneda Y; Usui Y; Tanaka R; Hase K; Namba K; Namba K; Kamoi K; Takase H; Matsumiya W; Kusuhara S; Takeda A; Yawata N; Yanai R; Hiyama T; Harada Y; Hashida N; Maruyama K; Nakai K; Taguchi R; Kaburaki T; Mizuki N; Goto H; Fujino Y; Takeuchi M
Frontiers in medicine 2022; 9: 999804


AIM: To investigate the causes of low prevalence of Fuchs' uveitis syndrome (FUS) in Japan. METHODS: Medical records of 160 patients diagnosed with FUS at 14 uveitis specialty facilities in Japan were reviewed retrospectively. RESULTS: In 160 FUS patients, mean follow-up period before referral to our uveitis facilities was 31.6 ± 50.9 months. The most common reason for referral was idiopathic uveitis (61.9%), followed by cataract (25.0%), high intraocular pressure (IOP) including glaucoma (16.3%), and FUS (14.4%). Unilateral involvement was 96.9%. The most frequent ocular finding of FUS was anterior inflammation (91.9%), followed by stellate-shaped keratic precipitates (88.1%), cataract/pseudophakia (88.1%), diffuse iris atrophy (84.4%), vitreous opacity (62.5%), heterochromia (53.1%) and high IOP including glaucoma (36.3%). As treatments of these ocular findings, cataract surgery was performed in 52.5%, glaucoma surgery in 10.6%, and vitrectomy in 13.8%. Mean logMAR VA was 0.28 ± 0.59 at the initial visit, and decreased significantly to 0.04 ± 0.32 at the last visit. Proportions of FUS patients with BCVA <0.1 and 0.1 to <0.5 decreased, while that of ≥0.5 increased at the last visit compared with the initial visit. CONCLUSIONS: Ocular findings of FUS in Japanese FUS patients were consistent with the characteristic features. The low prevalence of FUS in Japan may be a result of being overlooked and misdiagnosed as mild idiopathic uveitis, cataract, and/or glaucoma.

Department of Ophthalmology, National Defense Medical College, Tokorozawa, Japan.

Full article

Classification:

15 Miscellaneous



Issue 23-3

Change Issue


advertisement

Oculus